Chalfont St. Giles, UK (Apr. 16)-GE Healthcare, a unit of General Electric, acquired Wave Biotech LLC, a supplier of disposable manufacturing technologies and processing equipment for the biopharmaceutical industry.
Chalfont St. Giles, UK (Apr. 16)-GE Healthcare (www.gehealthcare.com), a unit of General Electric (Fairfield, CT, www.ge.com), acquired Wave Biotech LLC (Somerset, NJ, www.wavebiotech.com), a supplier of disposable manufacturing technologies and processing equipment for the biopharmaceutical industry. The deal also includes Wave Biotech’s European subsidiary, Wave Europe Pvt. Ltd (Cork, Ireland). Financial terms were not disclosed.
Wave Biotech focuses on developing disposable bioprocess equipment for operations traditionally requiring stainless-steel tanks and piping. Its products include bioreactors, mixing equipment, and equipment for fluid transfers. The company’s single-use bioreactors also are used to enable the manufacture of patient-specific cell- and gene-therapy products.
“The integration of single-use cell culture with GE Healthcare’s existing filtration and downstream operations will provide a host of new disposable solutions to this growing industry,” said Vijay Singh, president and founder of Wave Biotech, in a company release.
Wave Biotech has 70 employees and annual revenues of roughly $25 million. It operates research and development and manufacturing facilities in Somerset, New Jersey. Singh will continue to operate the business from the Somerset facility.
Singh was involved in developing wave-induced agitation for fluid mixing and oxygenation in inflated plastic bags as a replacement for stirred tank bioreactors. This concept was developed into the company’s “Wave Bioreactor,” which it introduced in 1998. Further technical innovations include the development of bags with internal filters (patents pending) for perfusion and the scale-up to culture volumes over 500 L. Spinoffs of the technology include “Wave Mixers,” which provide noninvasive sterile mixing, “Wave Warmers” for thawing applications, and instrumentation suitable for introduction into bags.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.